Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).
The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.
A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la sua partecipazione alla prossima Conferenza sull'Innovazione in Healthcare e Tecnologia di Jones a Las Vegas. L'azienda parteciperà a una chiacchierata informale mercoledì 9 aprile alle 11:30 PDT (14:30 EDT/18:30 GMT).
Il team di alta direzione dell'azienda sarà disponibile per incontri individuali durante la conferenza. Le parti interessate possono organizzare incontri tramite il loro rappresentante di Jones o contattando Yuki Gonzalez, Vice Presidente Marketing e Accesso Aziendale.
Una registrazione della chiacchierata informale sarà disponibile su Theravance.com nella sezione Investitori, Eventi e Presentazioni, e rimarrà accessibile per 30 giorni dopo l'evento.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado su participación en la próxima Conferencia de Innovación en Salud y Tecnología de Jones en Las Vegas. La compañía participará en una charla informal el miércoles 9 de abril a las 11:30 AM PDT (2:30 PM EDT/6:30 PM GMT).
El equipo de alta dirección de la empresa estará disponible para reuniones individuales durante la conferencia. Las partes interesadas pueden organizar reuniones a través de su representante de Jones o contactando a Yuki Gonzalez, Vicepresidente de Marketing y Acceso Corporativo.
Una grabación de la charla informal estará disponible en Theravance.com en la sección de Inversores, Eventos y Presentaciones, y permanecerá accesible durante 30 días después del evento.
Theravance Biopharma (NASDAQ: TBPH)는 라스베가스에서 열리는 Jones Healthcare 및 기술 혁신 컨퍼런스에 참여한다고 발표했습니다. 회사는 4월 9일 수요일 오전 11:30 PDT (오후 2:30 EDT/오후 6:30 GMT)에 파이어사이드 채팅에 참여할 예정입니다.
회사의 고위 경영진 팀은 컨퍼런스 기간 동안 개별 미팅을 위해 대기할 것입니다. 관심 있는 분들은 Jones 대표를 통해 미팅을 조정하거나 마케팅 및 기업 접근 담당 부사장인 Yuki Gonzalez에게 연락할 수 있습니다.
파이어사이드 채팅의 녹화본은 Theravance.com의 투자자 섹션, 이벤트 및 프레젠테이션에서 제공되며, 이벤트 후 30일 동안 액세스할 수 있습니다.
Theravance Biopharma (NASDAQ: TBPH) a annoncé sa participation à la prochaine Conférence sur l'Innovation en Santé et Technologie de Jones à Las Vegas. L'entreprise participera à une discussion informelle le mercredi 9 avril à 11h30 PDT (14h30 EDT/18h30 GMT).
Le comité de direction de l'entreprise sera disponible pour des réunions individuelles pendant la conférence. Les parties intéressées peuvent organiser des réunions par l'intermédiaire de leur représentant de Jones ou en contactant Yuki Gonzalez, Vice-présidente du Marketing et de l'Accès Corporate.
Un enregistrement de la discussion informelle sera disponible sur Theravance.com dans la section Investisseurs, Événements et Présentations, et restera accessible pendant 30 jours après l'événement.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der bevorstehenden Jones Healthcare und Technologie Innovationskonferenz in Las Vegas angekündigt. Das Unternehmen wird an einem informellen Gespräch am Mittwoch, den 9. April um 11:30 Uhr PDT (14:30 Uhr EDT/18:30 Uhr GMT) teilnehmen.
Das Senior Management-Team des Unternehmens wird während der Konferenz für Einzelgespräche zur Verfügung stehen. Interessierte Parteien können Meetings über ihren Jones-Vertreter oder durch Kontaktaufnahme mit Yuki Gonzalez, Vizepräsidentin für Marketing und Unternehmenszugang, arrangieren.
Eine Aufzeichnung des informellen Gesprächs wird auf Theravance.com im Bereich Investoren, Veranstaltungen und Präsentationen verfügbar sein und bleibt 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez, Vice President, Marketing & Corporate Access (ygonzalez@jonestrading.com).
A recording of the event will be available after the conference and may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. The recording will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302415277.html
SOURCE Theravance Biopharma, Inc.